[vrx123/Adobe Stock]
Boston-based Delix Therapeutics has won regulatory approval to commence a study of the non-hallucinogenic psychoplastogen DLX-001. Psychoplastogens are a class of drugs that have the potential to promote neuroplasticity, which refers to the brain’s ability to adapt and form new connections between neurons. That capability could enable improvements in conditions such as depression, anxiety and addiction.DLX-001 offers potential for a range of conditions, according to Retsina Meyer, head of corporate strategy at Delix. “The aperture for indications for psychoplastogens is broad and is even broader for our non-hallucinogenic compounds of this class,” Meyer said. DLX-001 holds promise for conditions where cortical dendritic/synaptic atrophy plays a role in the pathology. Such atrophy is involved in conditions ranging from major depressive disorder (MDD), schizophrenia, Parkinson’s disease…